Pre-Market Analysis: Pfizer Inc., Merck & Co. Inc., AbbVie Inc., and Zogenix
Editor Note: For more information about this release, please scroll to bottom.
LONDON, October 25, 2013
LONDON, October 25, 2013 /PRNewswire/ --
The U.S. equity market posted gains on Thursday, October 24, 2013, with the
S&P 500, the Dow Jones Industrial Average, and the NASDAQ Composite rising
0.33%, 0.62%, and 0.56%, respectively. Shares in major drug manufacturers
mostly ended on a lower note, even as the broader market advanced. The major
movers in the industry included Pfizer Inc. (NYSE: PFE), Merck & Company Inc.
(NYSE: MRK), AbbVie Inc. (NYSE: ABBV), and Zogenix Inc. (NASDAQ: ZGNX). All
these companies are tracked by AAAResearchReports.com. Free technical research
on PFE, MRK, ABBV, and ZGNX can be downloaded upon signing up at:
Pfizer Inc.'s shares ended Thursday's trading session 0.03% higher at $30.61,
after fluctuating between $30.56 and $30.91. A total of 25.60 million shares
were traded, which is below the daily average volume of 25.86 million. Pfizer
Inc.'s shares have gained 6.62% in the last one month and 4.54% in the
previous three months, outperforming the S&P 500, which has gained 3.22% and
3.92% during the respective periods. Furthermore, the company's stock is
trading near its 52-week high of $31.15 and above its 50-day and 200-day
moving averages of $28.78 and $28.54, respectively. Sign up and read the
complimentary report on PFE at:
Shares in Merck & Co. Inc. fell by 0.73% on Thursday, even as the broader
market posted gains. The company's shares closed the day at $46.22, after
trading between $46.19 and $46.86. A total of 11.20 million shares were
traded, which is below the daily average volume of 12.94 million. Despite
Thursday's losses, Merck & Co. Inc.'s stock is trading above its 200-day
moving average of $46.12. Additionally, the company's shares have fallen by
0.62% in the previous three trading sessions, underperforming the S&P 500,
which has gained 0.42% during the same period. The free report on MRK can be
downloaded by signing up now at:
AbbVie Inc.'s shares vacillated between $47.74 and $48.98 before ending the
day 0.83% lower at $47.93. A total of 5.08 million shares were traded, which
is above the daily average volume of 4.38 million. Despite Thursday's
pullback, the company's shares have gained 4.24% in the last one month and
9.83% in the previous three months, outperforming the S&P 500, which has
gained 3.22% and 3.92% during the respective periods. Further, AbbVie Inc.'s
stock is trading near its 52-week high of $49.31 and above its 50-day and
200-day moving averages of $45.17 and $42.39, respectively. A free report on
ABBV can be accessed by registering at:
On Thursday, Zogenix Inc.'s stock finished at $2.24, down 1.32% from the
previous day's closing price of $2.27. The company's shares oscillated between
$2.22 and $2.30 during the trading session. A total of 0.24 million shares
were traded, which is below the daily average volume of 0.68 million. Despite
Thursday's decline, the company's shares have surged 18.52% in the last one
month and 45.45% in the previous three months, outperforming the S&P 500,
which has gained 3.22% and 3.92% during the respective periods. Moreover,
Zogenix Inc.'s stock is trading above its 50-day and 200-day moving averages
of $1.96 and $1.68, respectively.
Register with AAA Research Reports and download research on ZGNX for free at:
1.This is not company news. We are an independent source and our views do
not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
only human and are prone to make mistakes. If you notice any errors or
omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
increase awareness for mentioned companies to our subscriber base and the
4.If you wish to have your company covered in more detail by our team, or
wish to learn more about our services, please contact us at
5.For any urgent concerns or inquiries, please contact us at
6.Are you a public company? Would you like to see similar coverage on your
company? Send us a full investors' package to
research@EquityNewsNetwork.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
SOURCE AAA Research Reports
Contact: Phone #: + 1 (646) 396-9126 Contact Name: Peter F. Jones Email ID:
Press spacebar to pause and continue. Press esc to stop.